Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

News provided by

May 21, 2013, 08:00 ET

REDWOOD CITY, Calif., May 21, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from ten studies in breast, colon and prostate cancer, including a large next generation sequencing (NGS) study, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2013 at McCormick Place in Chicago.

(Logo: http://photos.prnewswire.com/prnh/20130425/SF01493LOGO)

Presentations include:

Results from seven studies of the Oncotype DX® breast cancer test expanding the breadth and depth of information about the value of the test and its utility in real-world clinical practice
Health economics analysis of the Oncotype DX colon cancer test
Initial evaluation using quantitative RT-PCR on gene expression in normal-appearing prostate tissue for prediction of prostate cancer recurrence or death
Large NGS study on fixed paraffin-embedded breast cancer tissue to detect fusion transcripts associated with breast cancer progression

The majority of ASCO Annual Meeting abstracts are now publicly available on ASCO's website, www.asco.org.

Presentation details are as follows (all times are in Central Daylight Savings Time):

Breast Cancer

Saturday, June 1

Poster Discussion: "The relationship between quantitative HER2 gene expression by the 21-gene RT-PCR assay and adjuvant trastuzumab (H) benefit in NCCTG (Alliance) N9831" (Abstract #520)

Lead Author: Edith A. Perez, M.D., Mayo Clinic Cancer Center
Poster Time: 8:00 AM – 12:00 PM; Discussion Time: 12:00 PM-1:00 PM
Location: E Hall D1

Poster Presentation: "Initial results from the 21-gene breast cancer assay registry: A prospective observational study in patients (pts) with ER+, early-stage invasive breast cancer (EBC)" (Abstract #565)

Lead Author: Jeffrey L. Vacirca, M.D., North Shore Hematology/Oncology Associates
Session Time: 1:15 PM – 5:00 PM
Location: S Hall A2

Poster Presentation: "ADAPT: Adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer" (Abstract #TPS655)

Lead Author: Nadia Harbeck, M.D., Breast Center University of Munich, Germany
Session Time: 1:15 PM – 5:00 PM
Location: S Hall A2

Poster Presentation: "A comparative analysis of distant recurrence risk assessments by Oncotype DX recurrence score alone and integrated with clinicopathologic factors in early-stage breast cancer" (Abstract #598)

Lead Author: Ciara M. Kelly, M.B., Cork University Hospital
Session Time: 1:15 PM – 5:00 PM
Location: S Hall A2

Poster Presentation: "Ethnic differences in tumor proliferation in women with early-stage breast cancer" (Abstract #560)

Lead Author: Kevin Kalinsky, M.D., M.S., New York Presbyterian Hospital
Session Time: 1:15 PM – 5:00 PM
Location: S Hall A2

Poster Presentation: "Phase II trial evaluating the use of 21-gene recurrence score (RS) to select preoperative therapy in hormone receptor (HR)-positive breast cancer" (Abstract #562)

Lead Author: Amelia B. Zelnak, M.D., MSc, The Winship Cancer Institute of Emory University
Session Time: 1:15 PM – 5:00 PM
Location: S Hall A2

Sunday, June 2, 2013

Oral Presentation: "Prognostic impact of the 21-gene recurrence score in patients presenting with stage IV breast cancer" (Abstract #507)

Lead Author: Tari A. King, M.D., Memorial Sloan-Kettering Cancer Center
Presentation Time: 10:00 AM – 10:15 AM
Location: N Hall B1

Colon Cancer

Sunday, June 2

Poster Presentation: "Real-world comparative economics of a 12-gene assay for prognosis in stage II colon cancer" (Abstract #3640)

Lead Author: Tiffany Yu, B.S., B.A., Cedar Associates LLC
Session Time: 8:00 AM – 11:45 AM
Location: S Hall A2

Prostate Cancer

Saturday, June 1

Poster Discussion: "Evidence for a field effect in early prostate cancer (PCa): Gene expression profiles in normal-appearing prostate tissue (NT) adjacent to tumor (T) as predictors of clinical outcome" (Abstract #5029)

Lead Author: Eric A. Klein, M.D., Cleveland Clinic
Poster Time: 8:00 AM – 12:00 PM ; Discussion Time: 12:00 PM-1:00 PM
Location: Arie Crown Theater

Next Generation Sequencing

Monday, June 3

Poster Discussion: "Fusion transcript discovery in formalin-fixed paraffin-embedded human breast cancer tissues and its relation to tumor progression" (Abstract: 11018)

Lead Author: Yan Ma, Ph.D., Genomic Health, Inc.
Poster Time: 8:00 AM – 12:00 PM; Discussion Time: 11:30 AM – 12:30 PM
Location: S100A

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions. The company's lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease and the Oncotype DX prostate cancer test, which predicts disease aggressiveness in men with low risk disease. As of March 31, 2013, more than 19,000 physicians in over 70 countries had ordered more than 350,000 Oncotype DX tests. Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of renal cell cancers, as well as additional treatment decisions in breast, colon and prostate cancers. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter @GenomicHealth. To learn more about Oncotype DX tests, visit: www.OncotypeDX.com and www.mybreastcancertreatment.org and www.myprostatecancertreatment.org.

Forward Looking Statement: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to our ability to generate similar results in further studies; the applicability of clinical study results to actual outcomes; the ability of any tests the company may develop to optimize cancer treatment; the ability of the company to develop and commercialize additional tests in the future; the scope, success or results of clinical trials and the timing of such activities; and the ability of the company's tests to impact clinical practice. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of our tests; the risks associated with competition; the applicability of clinical study results to actual outcomes; the risks associated with the commercialization of current and future products; the risks and potential delays associated with such studies; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2013. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

SOURCE Genomic Health, Inc.